Multidisciplinary, inpatient directly observed therapy for HIV-1-infected children and adolescents failing HAART: A retrospective study

AIDS Patient Care and STDs

Volumn 20, Issue 4, 2006, Pages 275-284

  Parsons, Genevieve N ^a   Siberry, George K ^a,c   Parsons, J Kellogg ^a   Christensen, James R ^a,b   Joyner, Mary L ^a   Lee, Stephanie L ^a   Kiefner, Carolyn M ^a   Hutton, Nancy ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADOLESCENT; CD4 LYMPHOCYTE COUNT; DIRECTLY OBSERVED THERAPY; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DIRECTLY OBSERVED THERAPY; HIV INFECTIONS; HUMANS; INFANT; INPATIENTS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33646077882     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.20.275     Document Type: Review

References (19)

1. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003;17:1925-1932.
2. Englund JA, Raskino C, Vavro C, et al. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J 2004;23:15-22.
3. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001;13:27-40.
4. Steele RG, Grauer D. Adherence to antiretroviral therapy for pediatric HIV infection: Review of the literature and recommendations for research. Clin Child Fam Psychol Rev 2003;6:17-30.
5. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
6. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-1528.
7. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002;109:e61.
8. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999;18:682-689.
9. Katko E, Johnson GM, Fowler SL, Turner RB. Assessment of adherence with medications in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2001;20:1174-1176.
10. McNabb JJ, Nicolau DP, Stoner JA, Ross J. Patterns of adherence to antiretroviral medications: The value of electronic monitoring. AIDS 2003;17:1763-1767.
11. Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: Benefit or burden? AIDS Patient Care STDs 2002;16:527-535.
12. Liechty CA, Bangsberg DR. Doubts about DOT: Antiretroviral therapy for resource-poor countries. AIDS 2003;17:1383-1387.
13. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: A work in progress. Clin Infect Dis 2002;34:984-990.
14. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004;38(Suppl 5):S402-408.
15. Macalino GE, Mitty JA, Bazerman LB, Singh K, McKenzie M, Flanigan T. Modified directly observed therapy for the treatment of HIV-seropositive substance users: Lessons learned from a pilot study. Clin Infect Dis 2004;38(Suppl 5):S393-397.
16. Mitty JA, Macalino GE, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005;39:545-550.
17. Gigliotti F, Murante BL, Weinberg GA. Short course directly observed therapy to monitor compliance with antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2001;20:716-718.
18. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: A critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S98-102.
19. Berrien VM, Salazar JC, Reynolds E, McKay K. Adherence to antiretroviral therapy in HIV-infected pediatric patients improves with home-based intensive nursing intervention. AIDS Patient Care STDs 2004;18:355-363.